Combination checkpoint inhibition, angiogenic inhibition and hepatic artery infusion chemotherapy for disease control of advanced hepatocellular carcinoma

被引：0
作者：
Imtiaz, Sayed [1 ]
Sheikh, Mohd Raashid [1 ]
机构：
[1] Univ Southern Calif, Keck Sch Med, Dept Surg, Div Hepatobiliary Pancreas & Abdominal Transplant, 1520 San Pablo St,Suite 4300, Los Angeles, CA 90033 USA
来源：
CHINESE CLINICAL ONCOLOGY | 2024年 / 13卷 / 05期
关键词：
Hepatocellular; carcinoma; PD-1; VEGFR-2; FOLFOX;
D O I：
10.21037/cco-23-149
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：3
相关论文
共 8 条
  • [1] Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
    Finn, Richard S.
    Qin, Shukui
    Ikeda, Masafumi
    Galle, Peter R.
    Ducreux, Michel
    Kim, Tae-You
    Kudo, Masatoshi
    Breder, Valeriy
    Merle, Philippe
    Kaseb, Ahmed O.
    Li, Daneng
    Verret, Wendy
    Xu, Derek-Zhen
    Hernandez, Sairy
    Liu, Juan
    Huang, Chen
    Mulla, Sohail
    Wang, Yulei
    Lim, Ho Yeong
    Zhu, Andrew X.
    Cheng, Ann-Lii
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (20) : 1894 - 1905
  • [2] Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020)
    Haber, Philipp K.
    Puigvehi, Marc
    Castet, Florian
    Lourdusamy, Vennis
    Montal, Robert
    Tabrizian, Parissa
    Buckstein, Michael
    Kim, Edward
    Villanueva, Augusto
    Schwartz, Myron
    Llovet, Josep M.
    [J]. GASTROENTEROLOGY, 2021, 161 (03) : 879 - 898
  • [3] Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion A Randomized Clinical Trial
    He, MinKe
    Li, QiJiong
    Zou, RuHai
    Shen, JingXian
    Fang, WanQiang
    Tan, GuoSheng
    Zhou, YuanMin
    Wu, XiaoPing
    Xu, Li
    Wei, Wei
    Le, Yong
    Zhou, ZhongGuo
    Zhao, Ming
    Guo, Ying
    Guo, RongPing
    Chen, MinShan
    Shi, Ming
    [J]. JAMA ONCOLOGY, 2019, 5 (07) : 953 - 960
  • [4] Hepatic Arterial Infusion of Oxaliplatin Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial
    Li, Qi-Jiong
    He, Min-Ke
    Chen, Huan-Wei
    Fang, Wan-Qiang
    Zhou, Yuan-Min
    Xu, Li
    Wei, Wei
    Zhang, Yao-Jun
    Guo, Ying
    Guo, Rong-Ping
    Chen, Min-Shan
    Shi, Ming
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (02) : 150 - +
  • [5] Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
    Qin, Shukui
    Chan, Stephen L.
    Gu, Shanzhi
    Bai, Yuxian
    Ren, Zhenggang
    Lin, Xiaoyan
    Chen, Zhendong
    Jia, Weidong
    Jin, Yongdong
    Guo, Yabing
    Hu, Xiaohua
    Meng, Zhiqiang
    Liang, Jun
    Cheng, Ying
    Xiong, Jianping
    Ren, Hong
    Yang, Fang
    Li, Wei
    Chen, Yajin
    Zeng, Yong
    Sultanbaev, Alexander
    Pazgan-Simon, Monika
    Pisetska, Margaryta
    Melisi, Davide
    Ponomarenko, Dmitriy
    Osypchuk, Yurii
    Sinielnikov, Ivan
    Yang, Tsai-Sheng
    Liang, Xiao
    Chen, Chunxia
    Wang, Linna
    Cheng, Ann-Lii
    Kaseb, Ahmed
    Vogel, Arndt
    [J]. LANCET, 2023, 402 (10408) : 1133 - 1146
  • [6] BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
    Reig, Maria
    Forner, Alejandro
    Rimola, Jordi
    Ferrer-Fabrega, Joana
    Burrel, Marta
    Garcia-Criado, Angeles
    Kelley, Robin K.
    Galle, Peter R.
    Mazzaferro, Vincenzo
    Salem, Riad
    Sangro, Bruno
    Singal, Amit G.
    Vogel, Arndt
    Fuster, Josep
    Ayuso, Carmen
    Bruix, Jordi
    [J]. JOURNAL OF HEPATOLOGY, 2022, 76 (03) : 681 - 693
  • [7] Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
    Yau, Thomas
    Park, Joong-Won
    Finn, Richard S.
    Cheng, Ann-Lii
    Mathurin, Philippe
    Edeline, Julien
    Kudo, Masatoshi
    Harding, James J.
    Merle, Philippe
    Rosmorduc, Olivier
    Wyrwicz, Lucjan
    Schott, Eckart
    Choo, Su Pin
    Kelley, Robin Kate
    Sieghart, Wolfgang
    Assenat, Eric
    Zaucha, Renata
    Furuse, Junji
    Abou-Alfa, Ghassan K.
    El-Khoueiry, Anthony B.
    Melero, Ignacio
    Begic, Damir
    Chen, Gong
    Neely, Jaclyn
    Wisniewski, Tami
    Tschaika, Marina
    Sangro, Bruno
    [J]. LANCET ONCOLOGY, 2022, 23 (01) : 77 - 90
  • [8] Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study
    Zhang, Tian-Qi
    Geng, Zhi-Jun
    Zuo, Meng-Xuan
    Li, Ji-Bin
    Huang, Jin-Hua
    Huang, Zi-Lin
    Wu, Pei-Hong
    Gu, Yang-Kui
    [J]. SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2023, 8 (01)
1